Assessment of immunocompetence by the intake of Lactobacillus plantarum HOKKAIDO contained yogurt

Assessment of immunocompetence by the intake of Lactobacillus plantarum HOKKAIDO contained yogurt - Effects of Lactobacillus plantarum HOKKAIDO on immune functions

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014138

Enrollment

135

Registered

2014-06-02

Start date

2014-04-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low immune system

Interventions

Intake 90 g of yogurt containing Lactobacillus plantarum HOKKAIDO daily for 8 weeks. Intake 90 g of yogurt daily for 8 weeks. Intake 90 g of yogurt-like non-fermented products daily for 8 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subjects who show relatively low NK cell activity 2.Subjects who agree to participate in the current study with written informed consent

Exclusion criteria

Exclusion criteria: 1. Subjects who are under medication for chronic ailments. 2. Subjects with serious diseases and/or infections. 3. Subjects with clinical history of major gastrointestinal surgery. 4. Subjects with frequent complaints and/or symptoms relevant to post-menopausal events. 5. Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. 6. Subjects with serious anemia. 7. Subjects with a history of allergy to medicine and/or food, especially dairy products. 8. Subjects regularly on supplementation which would affect the immune system. 9. Subjects who often intake Hokkaido-strain containing products 10. Heavy smokers and alcohol addicts, or subjects with extremely irregular lifestyle. 11.Subjects who donated 400ml whole blood within 12 weeks or who donated plasma or platelets within 4 weeks prior to initiation of the current study. 12. Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the current study. 13. Subjects who participate in other clinical trials within the last one month prior to the current study. 14. Subjects who are not eligible due to physician's judgment

Design outcomes

Primary

Measure	Time frame
NK cell activity	—

Secondary

Measure	Time frame
Five fraction of leukocyte, IgG, IgE, IgM, IL-1, IL-4, IL-6, IL-8, IL-10, IL-12, T-Cho, LDL-Cho, HDL-Cho, TG, FBG, HbA1c, 25-OHD, MIF	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun Nishihira, M.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026